M
Marcus Ballinger
Researcher at Genentech
Publications - 92
Citations - 11652
Marcus Ballinger is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & Docetaxel. The author has an hindex of 32, co-authored 85 publications receiving 8680 citations. Previous affiliations of Marcus Ballinger include Ludwig Institute for Cancer Research & Cornell University.
Papers
More filters
Journal ArticleDOI
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer,Fabrice Barlesi,Daniel Waterkamp,Keunchil Park,Fortunato Ciardiello,Joachim von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,Manuel Cobo Dols,Diego Cortinovis,Joseph W. Leach,Jonathan Polikoff,Carlos H. Barrios,Fairooz F. Kabbinavar,Osvaldo Arén Frontera,Filippo de Marinis,Hande Turna,Jong Seok Lee,Marcus Ballinger,Marcin Kowanetz,Pei He,Daniel S. Chen,Alan Sandler,David R. Gandara +24 more
TL;DR: Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations, and overall survival improvement was similar in patients with squamous non-squamous lung cancer.
Journal ArticleDOI
Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial
Louis Fehrenbacher,Alexander I. Spira,Marcus Ballinger,Marcin Kowanetz,Johan Vansteenkiste,Julien Mazieres,Keunchil Park,David J. Smith,A. Artal-Cortes,Conrad R. Lewanski,Fadi Braiteh,Daniel Waterkamp,Pei He,Wei Zou,Daniel S. Chen,Jing Yi,Alan Sandler,Achim Rittmeyer +17 more
TL;DR: This open-label, phase 2 randomised controlled trial assessed efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analysed by PD-L1 expression levels on tumours and tumour-infiltrating immune cells and in the intention-to-treat population.
Journal ArticleDOI
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour,Jan Bogaerts,Andrea Marie Perrone,Robert Ford,Lawrence H. Schwartz,Lawrence H. Schwartz,Sumithra J. Mandrekar,Nan Lin,Saskia Litière,Janet Dancey,Alice P. Chen,F. Stephen Hodi,Patrick Therasse,Otto S. Hoekstra,Lalitha K. Shankar,Jedd D. Wolchok,Marcus Ballinger,Marcus Ballinger,Marcus Ballinger,Caroline Caramella,Elisabeth G.E. de Vries +20 more
TL;DR: This guideline describes a standard approach to solid tumour measurements and definitions for objective change in tumour size for use in trials in which an immunotherapy is used and defines the minimum datapoints required from future trials to facilitate the compilation of a data warehouse to later validate iRECIST.
Journal ArticleDOI
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara,Sarah M. Paul,Marcin Kowanetz,Erica B. Schleifman,Wei Zou,Yan Li,Achim Rittmeyer,Louis Fehrenbacher,Geoff Otto,Christine Malboeuf,Daniel S. Lieber,Doron Lipson,Jacob Silterra,Lukas C. Amler,Todd Riehl,Craig Cummings,Priti S. Hegde,Alan Sandler,Marcus Ballinger,David Fabrizio,Tony Mok,David S. Shames +21 more
TL;DR: It is shown that high bTMB is a clinically actionable biomarker for atezolizumab in NSCLC, and a blood-based DNA sequencing assay to infer tumor mutational burden in the absence of tumor biopsy predicts response to PD-L1 blockade in patients with non-small-cell lung cancer.
Journal ArticleDOI
Peripheral T cell expansion predicts tumour infiltration and clinical response
Thomas D. Wu,Shravan Madireddi,Patrícia de Almeida,Romain Banchereau,Ying-Jiun J. Chen,Avantika S. Chitre,Eugene Y. Chiang,Hina Iftikhar,William E. O'Gorman,Amelia Au-Yeung,Chikara Takahashi,Leonard D. Goldstein,Chungkee Poon,Shilpa Keerthivasan,Denise E. de Almeida Nagata,Xiangnan Du,Hyang Mi Lee,Karl L. Banta,Sanjeev Mariathasan,Meghna Das Thakur,Mahrukh Huseni,Marcus Ballinger,Ivette Estay,Patrick Caplazi,Zora Modrusan,Lélia Delamarre,Ira Mellman,Richard Bourgon,Jane L. Grogan +28 more
TL;DR: Large-scale single-cell sequencing of RNA and T cell receptors in samples from patients with cancer shows clonotypic expansion of effector-like T cells not only in tumour tissue but also in normal adjacent tissues and peripheral blood, which associates with clinical response to cancer immunotherapy.